Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared on X:
“I find this study very interesting. Very much unlike my experience as an oncologist in the U.S. where most patients I see want systemic therapy.
A very large Dutch population-based study
Among 13,756 patients with mPAC, 72% did not receive systemic therapy (ST)
- Independent predictors of no-ST included increasing age, worse WHO PS (>0–1), modified Glasgow Prognostic Score (mGPS) 1–2, Charlson Comorbidity index ≥ 2, and low socioeconomic position
- Reason for not receiving ST was mostly due to patient and family preference (39%), followed by patient factors (31%, comorbidity or impaired performance status (PS))
- Half of patients not receiving ST had a good PS (WHO 0–1) (50%), while this was 68% when not receiving ST was based on preference.
- Median overall survival was 42 days (no-ST) versus 213 days (ST).”
Title: Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study
Authors: Thijmen H.T. Broekman, Tara M. Mackay, Judith de Vos-Geelen, Geert A. Cirkel, Merlijn U.J.E. Graus, Jan-Willem B. de Groot, Marjolein Y.V. Homs, Saskia A.C. Luelmo, Leonie J.M. Mekenkamp, Mirte M. Streppel, Rogier P. Voermans, Miriam L. Wumkes, Marc G. Besselink, Lydia G. van der Geest, Johanna W. Wilmink
You can also read: FDA Approves Daraxonrasib: First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer